Rick Titcomb is an associate in the Austin office of Wilson Sonsini Goodrich & Rosati, where he practices corporate law and corporate finance. His practice includes representing and advising borrowers and lenders in a broad range of debt financing transactions, including acquisition finance, direct lending facilities, single-lender and syndicated credit facilities, ABL facilities, restructurings and workouts, cross-border transactions, and other complex financing transactions.
Prior to joining the firm, Rick was an associate at Simpson Thacher & Bartlett LLP.
Rick Titcomb is an associate in the Austin office of Wilson Sonsini Goodrich & Rosati, where he practices corporate law and corporate finance. His practice includes representing and advising borrowers and lenders in a broad range of debt financing transactions, including acquisition finance, direct lending facilities, single-lender and syndicated credit facilities, ABL facilities, restructurings and workouts, cross-border transactions, and other complex financing transactions.
Prior to joining the firm, Rick was an associate at Simpson Thacher & Bartlett LLP.
- J.D., Cornell Law School, 2019
Cum Laude; Myron Taylor Scholar; Managing Editor, Cornell International Law Journal; Managing Editor, LII Supreme Court Bulletin
- B.A., Political Science, University of Idaho, 2016Minor in Spanish, Summa Cum Laude, Phi Beta Kappa, Honors Program
- State Bar of Texas
- J.D., Cornell Law School, 2019
Cum Laude; Myron Taylor Scholar; Managing Editor, Cornell International Law Journal; Managing Editor, LII Supreme Court Bulletin
- B.A., Political Science, University of Idaho, 2016Minor in Spanish, Summa Cum Laude, Phi Beta Kappa, Honors Program
- State Bar of Texas
Select Matters
- Represented Amphastar Pharmaceuticals in connection with a $500 million senior secured term loan and $200 million senior secured revolving credit facility, the proceeds of which were used in part in the acquisition of certain assets from Eli Lilly
- Represented ImmunityBio, Inc., in connection with an up to $320 million royalty interest financing and equity investment by Oberland Capital
- Advised Twitter on matters related to its acquisition by Elon Musk and related entities
Select Matters
- Represented Amphastar Pharmaceuticals in connection with a $500 million senior secured term loan and $200 million senior secured revolving credit facility, the proceeds of which were used in part in the acquisition of certain assets from Eli Lilly
- Represented ImmunityBio, Inc., in connection with an up to $320 million royalty interest financing and equity investment by Oberland Capital
- Advised Twitter on matters related to its acquisition by Elon Musk and related entities
Both platforms will capitalize on proprietary tech, AI capabilities, and expanded resources to further expand in the U.S. The acquisition will see TravelPerk double its revenue in the U.S., following 65 percent year-over-year growth in the market in 2023. TravelPerk’s U.S.-based headcount and footprint expands to now include offices in Boston, Chicago, Los Angeles, and Miami. AmTrav will operate under the same brand, and the entire team will continue with the business going forward.
- Privacy Policy
- Terms of Use
- Accessibility